<DOC>
	<DOCNO>NCT02576145</DOCNO>
	<brief_summary>This study ass whether daclizumab impairs ability child receive kidney transplant elicit primary immune response . The anticipated time study treatment 1 day , target sample size 82 individual .</brief_summary>
	<brief_title>A Study Assess Immune Response Pediatric Kidney Transplant Recipients Treated With Daclizumab ( Zenapax )</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Primary renal transplant recipient 2 19 year age Receiving receive daclizumab previous 418 month Receiving receive daclizumab le ( &lt; ) 24 hour pretransplant additional course every week Single organ recipient ( kidney ) Previous vaccination tetanus toxoid ( TT ) prior transplant Receiving maintenance immunosuppression regimen calcineurin inhibitor , mycophenolate mofetil , prednisone ( equivalent corticosteroid ) Received intravenous gamma globulin TT vaccination since transplant Experienced rejection within 3 month receive study vaccination and/or treat lymphocyte preparation methylprednisolone reverse suspect acute rejection within 3 month receive study vaccination Received vaccine within 30 day receive study vaccination Received plasmapheresis treatment growth hormone treatment since transplant</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>